Clinical Trial Update: NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial [Phase 2]

View source ↗

Summary

Phase 2 trial update for Nal-IRI–based therapy (NalIRIFOX) before surgery in borderline resectable pancreatic ductal adenocarcinoma; the study is currently recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Borderline Resectable Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Onivyde (nal-IRI) (nanoliposomal irinotecan)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Borderline Resectable Pancreatic Ductal Adenocarcinoma | Phase 2 | Status: RECRUITING